AbbVie (ABBV) Tops Q4 EPS by 4c, Raises FY18 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- SpaceX slides, tech stocks dip — what’s moving markets
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BMO Capital Downgrades Abbvie (ABBV) to Underperform; 'Risk/Reward Skewed to the Downside'
January 29, 2018 7:34 AM ESTBMO Capital downgraded Abbvie (NYSE: ABBV) from Market Perform to Underperform with a price target of $95.00 (from $84.00).
Analyst Alex Arfaei commented, "Our thesis is unchanged, but the risk/reward in ABBV has meaningfully changed after its remarkable rise, leading us to... More
UPDATE: Leerink Partners Downgrades Abbvie (ABBV) to Market Perform, 'Limited Upside After Huge Run'
January 29, 2018 6:39 AM EST(Updated - January 29, 2018 7:18 AM EST)
(updated to add analyst comment)
Leerink Partners downgraded Abbvie (NYSE: ABBV) from Outperform to Market Perform with a price target of $127.00 (from $105.00).
Analyst Geoffrey Porges comments "After the dramatic move in AbbVies stock on... More
Abbvie (ABBV) PT Raised to $157 at SunTrust Robinson Humphrey; Premium Warranted
January 29, 2018 6:14 AM ESTSunTrust Robinson Humphrey raised its price target on Abbvie (NYSE: ABBV) to $157.00 (from $105.00) while maintaining a Buy rating.
Analyst John Boris said operational execution and pipeline warrant a premium.
... MoreAbbvie (ABBV) PT Raised to $130 at Cowen; Big Beat
January 26, 2018 11:16 AM ESTCowen raised its price target on Abbvie (NYSE: ABBV) to $130.00 (from $105.00) while maintaining an Outperform rating.
Analyst Steve Scala commented, "Q4 EPS and revenue well ahead of estimates. 2018 EPS guidance boosted sizably on strong operations and tax rate benefits. Plans for increasing shareholder... More
